Trials / Completed
CompletedNCT00728988
Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome
A Prospective Randomized, Open-Label, Parallel-Group Comparative Study: Atorvastatin Pre-Treatment Versus Usual Care In Asian Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 499 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This present study is specifically designed to examine the efficacy and safety of a high pre-treatment dose of atorvastatin in Asian patients with NSTE-ACS in China and the Republic of Korea, by using a treatment paradigm similar to that employed in the ARMYDA-ACS study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin | 80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days. |
| DRUG | Atorvastatin | 40mg daily after PCI for 30 days. |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2008-08-06
- Last updated
- 2021-02-21
- Results posted
- 2011-09-27
Locations
26 sites across 2 countries: China, South Korea
Source: ClinicalTrials.gov record NCT00728988. Inclusion in this directory is not an endorsement.